Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Article Details

Citation
Copy to clipboard

Jones RN, Huynh HK, Biedenbach DJ

Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Antimicrob Agents Chemother. 2004 Aug;48(8):3136-40.

PubMed ID
15273134 [ View in PubMed
]
Abstract

Doripenem (formerly S-4661), a new 1-beta-methyl carbapenem, was challenged with a worldwide collection of 394 drug-refractory isolates. For endemic extended-spectrum beta-lactamase- and stably derepressed AmpC-producing enteric bacilli, the doripenem MICs at which 90% of the isolates were inhibited (MIC90s) were 0.03 to 0.5 microg/ml, generally lower than those of comparator carbapenems. A greater proportion of strains among carbapenem-resistant nonfermentative gram-negative bacilli were inhibited by doripenem at < or =4 microg/ml, and doripenem was the most active carbapenem (MIC90, 1 to 4 microg/ml) against penicillin-resistant streptococci.

DrugBank Data that Cites this Article

Drugs